

ACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_UP, LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_UP

- LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_DN, LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_DN
- LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_NEGATIVE, LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_NEGATIVE
- HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_UP, HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LO
- RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_SIGNIFICANT_VARIATION_UP, RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_SIGNIFICANT_VARIATION_UP
- COLE_BLOOD_FLUZONE_FLUARIX_AGE_03_17YO_7DY_DN, COLE_BLOOD_FLUZONE_FLUARIX_AGE_03_17YO_7DY_DN
- FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_DN, FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_DN